GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The safety profile was consistent with previous studies with GLPG3667 Galapagos will evaluate al ...

Core Insights - Galapagos NV announced promising Phase 2 data for GLPG5101, a CAR T-cell therapy for high-risk mantle cell lymphoma (MCL), showing high complete response rates and minimal residual disease negativity with durable responses [1][5] Group 1: Study Results - The ATALANTA-1 study reported an objective response rate (ORR) of 100% and a complete response rate (CRR) of 96% among infused patients [5] - At a median follow-up of 9 months, both duration of response (DOR) and progression-free survival (PFS) rates were 83% [5] - Among minimal residual disease (MRD)-evaluated patients, 90% were MRD-negative at complete response, with 7 out of 9 MRD-negative patients remaining in complete response at the data cut-off [5] Group 2: Safety Profile - GLPG5101 demonstrated a favorable safety profile, with the most common Grade ≥ 3 treatment-emergent adverse events being hematologic [5] - No Grade ≥ 3 cytokine release syndrome (CRS) was observed, and only one case of Grade ≥ 3 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred [5] Group 3: Manufacturing and Administration - GLPG5101 is a second-generation anti-CD19/4-1BB CAR-T product administered as a single fixed intravenous dose, with a 7-day vein-to-vein time [1][4] - The study evaluated three dose levels: 50×10^6, 110×10^6, and 250×10^6 CAR+ viable T-cells [4] - The low dropout rate of 4% and elimination of the need for bridging therapy allowed more patients to access treatment [1][2] Group 4: Company Strategy - Galapagos intends to wind down its cell therapy activities while continuing to operate the business and conduct ongoing clinical studies [3] - The company remains open to viable proposals for acquiring all or part of its cell therapy business during the wind-down process [3]

Core Points - Galapagos NV received transparency notifications from Bank of America regarding changes in voting rights ownership [1][6] - Bank of America crossed the 5% threshold of Galapagos' voting rights on November 12, 2025, and subsequently fell below this threshold on November 14, 2025 [1][6] Summary of Transactions - On November 12, 2025, Bank of America held a total of 5.26% of voting rights, which included 0.26% direct voting rights and 5.00% equivalent financial instruments [3][10] - By November 14, 2025, this total decreased to 3.43%, comprising 0.16% direct voting rights and 3.28% equivalent financial instruments [2][3] Details of Voting Rights - The notifications indicated that on November 14, 2025, Bank of America Corporation owned 103,534 voting rights and 2,159,259 equivalent financial instruments, representing 3.43% of Galapagos' 65,897,071 outstanding shares [2][6] - In the previous notification, the holdings were 168,924 voting rights and 3,295,951 equivalent financial instruments, representing 5.26% [2][3] Breakdown of Voting Rights Holders - The breakdown of voting rights holders included various entities under Bank of America, with the largest being Merrill Lynch International, which had 65,070 voting rights [5][9] - The total voting rights held by Bank of America and its affiliates were detailed, showing a significant reduction in holdings from the previous notification [5][9] Equivalent Financial Instruments - The equivalent financial instruments held by Bank of America included various types of swaps and rights, totaling 2,159,259 instruments, which accounted for 3.28% of voting rights [7][11] - The notifications provided a detailed list of the types of financial instruments and their respective expiration dates and exercise periods [7][11]

Summary of Galapagos Conference Call Company Overview - **Company**: Galapagos (NasdaqGS:GLPG) - **Industry**: Biotechnology - **Current Focus**: Transitioning from cell therapy to building a new pipeline with existing cash reserves of approximately EUR 3 billion [2][3] Key Points and Arguments Strategic Vision and Transformation - Galapagos is undergoing a transformation, moving away from its cell therapy business due to market challenges and focusing on new opportunities that can create more shareholder value [4][6] - The decision to abandon the planned separation into two entities was based on the evolving cell therapy market and the potential for better returns by reallocating capital [4][5] Financial Position - The company has a strong cash position of EUR 3 billion, with expectations to end the year with EUR 2.975 billion to EUR 3.025 billion [7][8] - Anticipated additional operating costs for winding down the cell therapy business are estimated at EUR 100 million to EUR 125 million, with restructuring costs of EUR 150 million to EUR 200 million [8][9] - Galapagos expects to be cash flow neutral or positive by year-end 2026, supported by interest income and tax credits [9][10] Business Development and M&A Strategy - The company is actively seeking de-risked opportunities for acquisitions and partnerships, particularly in immunology and oncology [12][13] - Galapagos is open to both M&A and in-licensing deals, with a focus on late-stage development programs that can create significant value [14][15] - The partnership with Gilead, which owns 25% of Galapagos, is crucial for sourcing and evaluating potential deals [18][21] Cell Therapy Business Wind Down - The decision to wind down the cell therapy business was based on a thorough analysis of market opportunities and capital requirements [23][24] - The wind down process is currently underway, with expectations to conclude discussions with works councils by Q1 of the following year [25][26] - Galapagos remains open to selling the cell therapy business for EUR 1 if a viable proposal arises [27][28] TIC2 Immunology Program - The TIC2 program is the only remaining asset from the legacy platform, with high confidence in its clinical response potential [31][32] - The company is considering partnering for the TIC2 program if it does not meet competitive differentiation standards [31][32] Future Catalysts - Investors should look for clarity on the wind down process, updates on the TIC2 program, and the first business development deals as potential catalysts for the company's future [33][34] Additional Important Information - The relationship with Gilead is expected to evolve positively, with discussions on renegotiating terms to enable more collaborative opportunities [19][20] - The company is focused on ensuring a smooth transition for patients currently involved in clinical trials during the wind down of the cell therapy business [29][30]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Financial Data and Key Metrics Changes - Total operating loss from continuing operations for the first nine months of 2025 amounted to EUR 462.2 million, compared to an operating loss of EUR 125.6 million for the same period in 2024 [24] - Net other financial income for the first nine months of 2025 was EUR 30.4 million, down from EUR 71.7 million in the same period of 2024 [25] - Cash and cash equivalents and current financial investments totaled EUR 3.05 billion on September 30, 2025, compared to EUR 3.32 billion on December 31, 2024 [26] Business Line Data and Key Metrics Changes - The company intends to wind down the self-therapy business due to significant ongoing investment requirements and lack of viable acquisition proposals [6][7] - The remaining organization will focus on transformational business development and maintaining a dedicated presence at headquarters in Mechelen, Belgium [10] Market Data and Key Metrics Changes - The cash balance of approximately EUR 3 billion represents about EUR 46 per share, generating significant interest income [12] - The company expects to receive tax receivables of approximately EUR 20 million to EUR 35 million per year over the next three years [13] Company Strategy and Development Direction - The company is undergoing a transformation, focusing on business development and rebuilding its pipeline after the decision to wind down the self-therapy business [4][5] - The strategy includes identifying and executing on opportunities that can enhance the standard of care in various diseases, particularly in partnership with Gilead [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, emphasizing the importance of a disciplined approach to business development and the potential for significant value creation [28] - The company anticipates being cash flow neutral to positive by the end of 2026, excluding any business development activities [27] Other Important Information - The company has welcomed four new board members to enhance its leadership team [9] - The wind-down process is expected to conclude in the first quarter of 2026, with consultations ongoing with works councils in Belgium and the Netherlands [11] Q&A Session Summary Question: What assumptions are behind the expectation of achieving cash flow neutral status by year-end 2026? - The assumptions include interest income based on forward rates, tax credits, and the completion of the wind-down process [30] Question: What types of opportunities are in the deal funnel? - The focus is on clinically de-risked mid to late-stage opportunities, particularly in oncology and immunology, with a preference for collaboration with Gilead [31][32] Question: How does the company balance being conservative with pursuing business development? - The company aims to leverage its cash balance and existing assets while ensuring any new opportunities create a positive return [33] Question: What expectations does the company have for Gilead's contribution to the deal process? - Gilead is expected to provide expertise in diligence and potentially contribute capital for development [35] Question: What is the timeline for the wind-down process of the cell therapy business? - The wind-down process is expected to be concluded in Q1 2026, with the company open to viable proposals during this time [44] Question: Will potential transactions bring in R&D capabilities? - The company is flexible regarding R&D capabilities, considering both acquiring teams and funding external parties [50]

Strategic Transformation - Galapagos is executing a strategic transformation, including the intention to wind down the cell therapy business, subject to works council consultations[13, 17] - The company expects to be cash flow neutral to positive by YE26, excluding BD and currency fluctuations[18] - A lean organization of 35-40 employees is expected by YE26, focused on transformative business development[18, 60] Financial Performance & Outlook - Nine-month total revenues increased by 6% to €211.4 million[64] - R&D expenses increased by 48% to €351.9 million[64] - An impairment loss of €204.8 million was recorded for the Cell Therapy business[64, 70] - The company anticipates approximately €2.975 - €3.025 billion in cash and investments at YE25[24] Business Development Strategy - Business development is a core strategy, leveraging a unique partnership with Gilead[37, 38] - The company is open to opportunities across diseases, modalities, geographies, and deal types[51] - A disciplined approach to capital deployment aims to maximize near- and long-term value creation[39, 40]

Financial Performance - Galapagos reported total net revenues of €211.4 million for the first nine months of 2025, a 6% increase from €200.1 million in the same period of 2024[12]. - Supply revenues increased by 53% to €29.3 million, while collaboration revenues rose by 1% to €182.1 million[7]. - The company incurred an operating loss of €462.2 million for the first nine months of 2025, compared to a loss of €125.6 million in the same period of 2024, largely due to a €204.8 million impairment related to the cell therapy business[10]. - Net loss from continuing operations for the first nine months of 2025 was €463.0 million, compared to a loss of €20.4 million in the same period of 2024[14]. - The company reported a net profit from discontinued operations of €1.7 million for the first nine months of 2025, a significant decrease from €69.2 million in the same period of 2024[15]. - Basic and diluted loss per share for the nine months ended September 30, 2025, was €7.00, compared to earnings of €0.74 per share in 2024[27]. - The total comprehensive loss for the period was €(467,806) thousand, primarily due to a net loss of €(461,262) thousand[33]. Research and Development - Research and development expenses increased by 48% to €351.9 million, driven by higher personnel costs and impairment on fixed assets[12]. - Research and development expenses increased to €351,909 thousand in 2025, up 47.6% from €238,270 thousand in 2024[27]. - The company reported an impairment of the cell therapy business amounting to €204,753 thousand in 2025[27]. Cash and Investments - Galapagos expects to end 2025 with approximately €2.975 billion to €3.025 billion in cash and financial investments, excluding business development activities[19]. - Financial investments and cash totaled €3,050.1 million as of September 30, 2025, down from €3,317.8 million at the end of 2024[17]. - Cash and cash equivalents remained stable at €64,458 thousand as of September 30, 2025, compared to €64,239 thousand at the end of December 2024[29]. - Cash and cash equivalents at the end of the period were €64,458 thousand, up from €55,523 thousand[31]. - The company made a net sale of financial investments amounting to €152.4 million during the reporting period[34]. Operational Changes - The planned wind down of the cell therapy business could result in an operating cash impact of €100 million to €125 million from Q4 2025 through 2026[19]. - The company anticipates being cash flow neutral to positive by the end of 2026 if the wind down is completed[19]. - The company anticipates a transformation strategy that includes winding down its cell therapy business, which may involve workforce reductions and site closures[24]. Cash Flow - The operational cash burn for the first nine months of 2025 amounted to €145.1 million, with an increase in cash and cash equivalents of €3.3 million[34]. - Net cash flows used in operating activities were €(209,995) thousand, compared to €(260,657) thousand in the previous period[31]. - Net cash flows generated from investing activities were €216,191 thousand, an increase from €152,237 thousand in the prior period[31]. - Interest received was €22,310 thousand, a decrease from €60,523 thousand in the previous period[31]. - The company issued a convertible loan to a third party amounting to €20,000 thousand[31]. Assets and Equity - Total assets decreased to €3,511,914 thousand as of September 30, 2025, from €4,135,719 thousand at the end of December 2024[29]. - Total equity fell to €2,446,963 thousand as of September 30, 2025, down from €2,896,939 thousand at the end of December 2024[29].

Core Insights - Galapagos NV has concluded its strategic review process, deciding to wind down its cell therapy business to optimize capital allocation for a sustainable future [1][4] - The company has a robust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025, and expects to end the year with approximately €2.975 billion to €3.025 billion [1][15] - Leadership changes have been made to align with the new strategic direction, enhancing corporate and business development capabilities [3][6] Financial Performance - Total net revenues for the first nine months of 2025 reached €211.4 million, a 6% increase from €200.1 million in the same period of 2024 [5][9] - The company reported an operating loss of €462.2 million for the first nine months of 2025, significantly higher than the €125.6 million loss in the same period of 2024, primarily due to a €204.8 million impairment related to the cell therapy business [7][10] - Net loss from continuing operations was €463.0 million for the first nine months of 2025, compared to a net loss of €20.4 million for the same period in 2024 [10][12] Strategic Focus - The management aims to strategically deploy capital in a disciplined manner, focusing on value-accretive transactions, particularly in small molecule and biologics programs in immunology and oncology [1][4] - The company is actively evaluating opportunities and believes its partnership with Gilead provides a strategic advantage in pursuing these opportunities [1][4] Operational Changes - The wind down of the cell therapy business is expected to impact approximately 365 employees across various locations, with the remaining organization projected to consist of 35-40 employees by the end of 2026 [4][15] - The company anticipates being cash flow neutral to positive by the end of 2026, excluding any business development activities and currency fluctuations, if the wind down is successfully implemented [1][15] Clinical Pipeline - Galapagos is advancing its clinical pipeline, including GLPG5101, a CD19 CAR-T candidate in Phase 1/2 trials, and GLPG3667, a small molecule TYK2 inhibitor in Phase 3-enabling studies [5][6]

Core Insights - The article discusses the presentation of new Phase 2 data for GLPG5101, a CAR-T cell therapy candidate by Galapagos, at the upcoming ASH Annual Meeting, highlighting its potential in treating high-risk relapsed/refractory mantle cell lymphoma and large B-cell lymphoma [1][2][3] Group 1: Clinical Data Presentation - Two abstracts will present new Phase 2 data for GLPG5101 in relapsed/refractory mantle cell lymphoma (R/R MCL) and large B-cell lymphoma (R/R DLBCL) [2] - The oral presentation will showcase high complete response rates and minimal residual disease negativity, with low rates of severe grade toxicities, demonstrating the therapy's effectiveness [5][6] - The data supports the hypothesis that rapid delivery of fresh, early-memory enriched CAR-T cells can improve patient outcomes [3][5] Group 2: Manufacturing and Administration - GLPG5101 is manufactured using an innovative platform that allows for a median vein-to-vein time of seven days, facilitating broader access to cell therapy [1][9] - The manufacturing process includes a decentralized, automated system that enhances the quality control and patient experience [9] - The therapy is administered as a single fixed intravenous dose, with ongoing evaluations of safety and efficacy in the ATALANTA-1 study [8][9] Group 3: Company Showcase and Future Directions - Galapagos will host a company showcase titled "Fast, Fresh, Fit," focusing on the transformative potential of their cell therapy approach [2] - The ATALANTA-1 study is currently enrolling patients in the U.S. and Europe, with a primary objective to evaluate the Objective Response Rate (ORR) [8] - The company is also considering proposals for acquiring its cell therapy business during its ongoing transformation [13]